Table of Contents September 01, 2017; Volume Issue Supplement 2

  1. Herrmann, Ken

    1. CXCR4 Ligands: The Next Big Hit?
      Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann and Hans-Jürgen Wester
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 77S-82S; DOI: https://doi.org/10.2967/jnumed.116.186874
    2. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
      Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann and Frederik L. Giesel
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 67S-76S; DOI: https://doi.org/10.2967/jnumed.116.186767
    3. Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview
      Ken Herrmann, Steven M. Larson and Wolfgang A. Weber
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 1S-2S; DOI: https://doi.org/10.2967/jnumed.117.199570

  2. Hetkamp, Philipp

    1. Iodine Symporter Targeting with 124I/131I Theranostics
      James Nagarajah, Marcel Janssen, Philipp Hetkamp and Walter Jentzen
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 34S-38S; DOI: https://doi.org/10.2967/jnumed.116.186866

  3. Hofman, Michael S.

    1. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
      Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann and Frederik L. Giesel
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 67S-76S; DOI: https://doi.org/10.2967/jnumed.116.186767

  4. Jalving, Mathilde

    1. Theranostics Using Antibodies and Antibody-Related Therapeutics
      Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 83S-90S; DOI: https://doi.org/10.2967/jnumed.116.186940

  5. Janssen, Marcel

    1. Iodine Symporter Targeting with 124I/131I Theranostics
      James Nagarajah, Marcel Janssen, Philipp Hetkamp and Walter Jentzen
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 34S-38S; DOI: https://doi.org/10.2967/jnumed.116.186866

  6. Jentzen, Walter

    1. Iodine Symporter Targeting with 124I/131I Theranostics
      James Nagarajah, Marcel Janssen, Philipp Hetkamp and Walter Jentzen
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 34S-38S; DOI: https://doi.org/10.2967/jnumed.116.186866

  7. Kok, Iris C.

    1. Theranostics Using Antibodies and Antibody-Related Therapeutics
      Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 83S-90S; DOI: https://doi.org/10.2967/jnumed.116.186940

  8. Kopka, Klaus

    1. Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
      Klaus Kopka, Martina Benešová, Cyril Bařinka, Uwe Haberkorn and John Babich
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 17S-26S; DOI: https://doi.org/10.2967/jnumed.116.186775
    2. Identification of Ligands and Translation to Clinical Applications
      Uwe Haberkorn, Walter Mier, Klaus Kopka, Christel Herold-Mende, Annette Altmann and John Babich
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 27S-33S; DOI: https://doi.org/10.2967/jnumed.116.186791

  9. Kratowchil, Clemens

    1. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
      Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann and Frederik L. Giesel
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 67S-76S; DOI: https://doi.org/10.2967/jnumed.116.186767

  10. Krenning, Eric P.

    1. Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
      Rachel Levine and Eric P. Krenning
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 3S-9S; DOI: https://doi.org/10.2967/jnumed.116.186502
« Previous (Pages : 1 2 3 4 5 6 ... 6) Next »
Back to top

In this issue